B-CLL Sample1 - Human B-chronic lymphocytic leukemia - Sample1
Homo sapiens
Scientific Name
Homo Sapiens
sex
male
Submission description
In B-chronic lymphocytic leukemia (B-CLL) the interaction between leukemic cells and the environmental niches confers drug resistance and promotes tumor cells survival. The Bruton's tyrosine kinase inhibitor ibrutinib is one of the first-in-class molecules available for the treatment of B-CLL patients able to disrupt the microenvironment protection. However, the emerging mechanisms of resistance affecting patients' survival call for new therapeutic strategies. The purpose of the current study was to investigate the ability of ibrutinib plus the MDM2-inhibitor nutlin-3 to counteract the tumor microenvironment protective effect
Submission identifier
GSB-1351
Submission title
Dual BTK and MDM2 inhibition effects in microenvironment protected chronic lymphocytic leukemia cells
cell_type
B-cell
geographic location (country and/or sea)
Italy
tissue_type
Blood
ENA-FIRST-PUBLIC
2019-09-30
ENA-LAST-UPDATE
2019-09-30